Citryll

📍 Following our recent €85 million Series B raise, our CEO Eduardo Bravo reflects on Citryll's breakthrough year in NET biology and shares our vision for 2025. Beyond the funding milestone, 2024 has marked significant advances in our mission to transform immune-mediated inflammatory disease treatment – from completing our Phase 1 trial to strengthening our leadership team and expanding our understanding of NETs. 🔗 Read Eduardo's full perspective on how we're pioneering our NET-targeted approach: https://lnkd.in/dpP9_NJm #Biotech #DrugDevelopment #Innovation #SeriesB

Citeline’s Kevin Grogan caught up with our CEO Eduardo Bravo to discuss this week’s Series B financing, Citryll’s NET-targeting approach and our vision for transforming the treatment of inflammatory disease.   You can read the full piece in Scrip here: https://lnkd.in/dH3mKPPE   #Biotech #SeriesB #Innovation #DrugDevelopment

We are proud to announce that we have raised €85 million in an oversubscribed Series B financing led by Johnson & Johnson Innovation JJDC Inc, Forbion and Novartis Venture Fund, with the participation of Pureos Bioventures, alongside our committed existing shareholders.    This funding will be used to accelerate the development of CIT-013, our first-in-class monoclonal antibody which targets Neutrophil Extracellular Traps. This will advance CIT-013 into two Phase 2a #clinicaltrials, exploring its potential in rheumatoid arthritis and hidradenitis suppurativa.    We’re delighted to have such a high-quality syndicate of investors who share our vision, and we look forward to providing a more effective treatment option for patients who have long struggled with inadequate disease control.    To learn more, watch the video below and read the full press release here: https://lnkd.in/duuMnhNR #Biotech #HealthcareInnovation #SeriesB #Fundraise

📢 Our CEO Eduardo Bravo will be in London next week representing Citryll at the Jefferies London Healthcare Conference 2024, from 19-21 November.   At this milestone 15th edition of Europe's largest healthcare conference, we look forward to connecting with industry leaders and sharing the progress of CIT-013, our innovative approach to treating immune-mediated inflammatory diseases.    📌Interested in meeting? We'd love to connect in London.   Find out more about what we do at Citryll: https://citryll.com/   #JefferiesHealthcare #Citryll #Biotech #NETosis  

📢 Join the amazing Citryll team! We're hiring! At Citryll, we are on a mission to transform the treatment landscape for immune-mediated inflammatory diseases. As we advance into Phase 2a clinical studies with our leading asset, CIT-013, we are expanding our talented team to drive innovation forward. If you're passionate about making a real impact in the biotech industry, check out our latest job openings! Why work with us? ✅ A collaborative and inclusive work environment ✅ Opportunities for continuous learning and career growth ✅ An opportunity to advance groundbreaking therapies that can change patients’ lives 📩 How to Apply Eager to join Citryll in this exciting journey? Explore our current vacancies and apply here https://lnkd.in/dNZMcWtp Lets make a difference together! #Hiring #BioTech #Citryll

📢 Citryll will be attending the American College of Rheumatology Convergence 2024, this week in Washington, D.C., 14-19 November!   Our Chief Technology Officer Renato Chirivi will be delivering an exciting plenary presentation on "Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration", on Saturday, November 16th, 10:15 ET.   Joining Renato at ACR will be Eduardo Bravo, CEO, Maarten Kraan, CMO, and Leonie Middelink, Head of Clinical Operations.   Be sure to come along to engage with our team and dive into our latest developments in rheumatology and learn more about our novel approach to treating immune-mediated inflammatory diseases! 👋   #ACR24 #Rheumatology #Innovation #BioTech #Citryll

📌 Next week, our Chief Medical Officer Maarten Kraan will be attending the 8th Annual Dermatology Drug Development Summit in Boston, MA.   Maarten will be leading an engaging session on "Hidradenitis Suppurativa: An Evolving Drug Development Landscape", discussing current pathophysiology insights, unmet needs, and emerging therapeutic targets in HS drug development, on November 12, at 8:00 ET.   Join us for this opportunity to participate in dynamic discussions about overcoming the limitations of current anti-inflammatory approaches!    🔗 Learn more about the event here: https://lnkd.in/ea3brkF   #Dermatology #Innovation #Citryll #BioTech #HS #HidradenitisSuppurativa

Our Chief Business Officer Tim Schenk is at Bio-Europe in Stockholm, Sweden today! This year, BioEurope is celebrating 30 years of facilitating partnerships and taking part is a great opportunity to forge meaningful connections across the industry. Let us know if you’re around!   Citryll is pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a fundamental component of the inflammatory process that has yet to be addressed therapeutically. Learn more about Citryll here: https://lnkd.in/dTyMdY24   #Citryll #BIOEurope #Biotech #networking

Our Head of Clinical Operations, Leonie Middelink, and Scientist, Stephanie van Dalen, are looking forward to attending the 9th Annual Symposium on Hidradenitis Suppurativa Advances, taking place in Austin, Texas, from 1-3 November. During the conference Stephanie will share a poster on Citryll’s latest research in Hidradenitis Suppurativa (HS), titled "Neutrophil Extracellular Traps in HS skin and serum as a target for CIT-013, a NET targeting therapy". Be sure to check out our poster and discover how Citryll is revolutionizing the world of immune-mediated inflammatory diseases! Learn more about SHSA: https://lnkd.in/gBZZwg4f #SHSA2024 #Dermatology #NETosis #Citryll #ClinicalResearch

This Saturday is #WorldArthritisDay, a global initiative dedicated to raising awareness about rheumatic and musculoskeletal diseases (RMDs), including Rheumatoid Arthritis (RA) —one of the key conditions we are seeking to address at Citryll. According to EULAR - European Alliance of Associations for Rheumatology, RMDs affect over 120 million people in Europe alone, and RA is the most common inflammatory arthritis. Such diseases make daily tasks both challenging and painful for those affected. Join us in raising awareness and highlighting the urgent need for continued research in arthritis and related diseases. Together, we can work towards better treatments and brighter futures for those affected! Learn more here: https://lnkd.in/e8T-u25K #RheumatoidArthritis #awareness #inflammation #NETosis #WAD2024